RedHawk Holdings Corp. has announced they have successfully completed the independent laboratory testing of its newly designed SANDD Pro™ needle incineration device. Testing was performed by Intertek PLC (“Intertek”) to independently confirm the SANDD Pro™ meets the safety requirements of both International Electrotechnical Commission 61010-1 and Underwriter Laboratories 61010-1 for the United States, Canada, and Europe; Certification Bodies Scheme for the United States, Canada, and Europe; and, Electrical Testing Laboratories Listing for the United States and Canada.
Intertek is a leading total quality assurance provider to industries worldwide with more than 46,000 employees in 1,000 locations in over 100 countries based in the UK. Intertek testing ensures products meet quality, health, environmental, safety, and social accountability standards for virtually any market around the world. Intertek holds extensive worldwide accreditations and recognitions.
“The successful independent lab testing of our newly designed SANDD Pro™ needle incineration unit was the final step before commencing production,” commented G. Darcy Klug, RedHawk’s Chairman, and Interim Chief Executive Officer. “We can now begin the production process and we expect to launch sales and leasing of theSANDD Pro™ needle incineration device, coupled with certain bio-hazard waste disposal services, during the summer of 2020.”
The SANDD Pro™ is capable of incinerating hypodermic needles 18-gauge and higher, up to 8 inches in length. The SANDD Pro™ technology also features a separate portable, rechargeable, lithium-ion battery-operated unit (the “SANDD Pro™ – Portable”) capable of incinerating as many as 300 needles, ranging in gauges as thick as 21 gauge and lengths up to 8″ on a single charge. RedHawk believes the SANDD Pro™ – Portable will be ideal for field use by first responders, home health care nurses, veterinarians, and home use injectors. The SANDD Pro™ is both FDA approved and OSHA compliant.